Dongbao Bio released its 2026 half-year report. Net profit attributable to the parent in the first half was 37.4 million yuan, up 1.2% year on year. Operating revenue was 415 million yuan, up 12.4% year on year. Net profit attributable to the parent excluding non-recurring items was 33.6 million yuan, up 0.5% year on year. Net operating cash flow was 54.52 million yuan, up 8.4% year on year. Second-quarter operating revenue was 224 million yuan, up 23.8% year on year, while net profit attributable to the parent was 17.71 million yuan, down 1.2% year on year. Leveraging its collagen extraction strengths, the company is implementing a collagen plus strategy covering products such as gelatin, collagen, and empty capsules, and said it has consolidated its competitive edge in niche markets including pharmacopoeia grade-two gelatin and empty capsules.
Baotou Dongbao Bio-Tech Co LtdNet profit up 1.2% but Q2 profit down 1.2%; revenue growth strong, mixed results.
